China Historical Cash Flow
| SXTC Stock | USD 0.43 0.02 4.88% |
Analysis of China SXT cash flow over time is an excellent tool to project China SXT Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Operating Activities of 780.8 K or End Period Cash Flow of 9.2 M as it is a great indicator of China SXT ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining China SXT Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether China SXT Pharmaceuticals is a good buy for the upcoming year.
China |
About China Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in China balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which China's non-liquid assets can be easily converted into cash.
China SXT Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by China SXT Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of China SXT operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from China SXT's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into China SXT Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, China SXT's Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 918.9 K, whereas Change To Inventory is projected to grow to (162.7 K).
| 2024 | 2025 (projected) | Sale Purchase Of Stock | 5.8M | 5.2M | Stock Based Compensation | 316.9K | 301.0K |
China SXT cash flow statement Correlations
Click cells to compare fundamentals
China SXT Account Relationship Matchups
High Positive Relationship
High Negative Relationship
China SXT cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 38.6K | (180.8K) | 409.0K | (190.3K) | (171.3K) | (162.7K) | |
| Change In Cash | 6.1M | 2.2M | 1.8M | (5.3M) | (4.8M) | (4.5M) | |
| Net Borrowings | 2.6M | 5.6M | 12.4M | (1.0M) | (1.2M) | (1.1M) | |
| Free Cash Flow | (1.4M) | 205.8K | (151.4K) | (1.9M) | (1.7M) | (1.7M) | |
| Change In Working Capital | (1.6M) | 1.9M | 1.4M | (381.6K) | (438.8K) | (416.9K) | |
| Begin Period Cash Flow | 7.3M | 13.4M | 15.6M | 17.4M | 20.0M | 21.0M | |
| Total Cashflows From Investing Activities | (610.1K) | (5.5M) | (5.8M) | (46.9K) | (42.2K) | (44.3K) | |
| Other Cashflows From Financing Activities | 12.5M | (4.3M) | (3.3M) | (3.9M) | (3.5M) | (3.4M) | |
| Depreciation | 345.4K | 320.0K | 250.2K | 203.2K | 233.7K | 238.2K | |
| Other Non Cash Items | 1.6M | 1.1M | 408.7K | 996.7K | 897.0K | 918.9K | |
| Capital Expenditures | 93.0K | 62.5K | 70.7K | 7.1K | 6.4K | 6.0K | |
| Total Cash From Operating Activities | (1.3M) | 268.3K | (80.8K) | (1.9M) | (1.7M) | (1.6M) | |
| Change To Account Receivables | (519.2K) | 831.5K | 912.9K | (321.4K) | (369.6K) | (388.1K) | |
| Change To Operating Activities | 517.5K | 1.4M | (256.4K) | 826.3K | 743.6K | 780.8K | |
| Net Income | (2.7M) | (5.7M) | (5.9M) | (3.1M) | (2.8M) | (2.9M) | |
| Total Cash From Financing Activities | 12.4M | 1.6M | 2.9M | (2.6M) | (3.0M) | (2.9M) | |
| End Period Cash Flow | 13.4M | 15.6M | 17.4M | 12.1M | 13.9M | 9.2M | |
| Other Cashflows From Investing Activities | 3.1M | 15.6K | 58.4K | 33.5K | 38.5K | 40.4K | |
| Change To Netincome | 82.3K | 5.5M | 1.6M | 3.8M | 4.3M | 4.5M | |
| Change To Liabilities | (567.3K) | 302.3K | (619.5K) | (22.8K) | (26.2K) | (27.5K) | |
| Investments | (8.8M) | (46.9K) | (12.3K) | 26.4K | 30.4K | 31.9K | |
| Stock Based Compensation | 1.3M | 2.3M | 554.6K | 352.1K | 316.9K | 301.0K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.71) | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.